Artwork

内容由Darshan Kulkarni提供。所有播客内容(包括剧集、图形和播客描述)均由 Darshan Kulkarni 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Congruency Review: The Game Changer

2:53
 
分享
 

Manage episode 398035284 series 3506216
内容由Darshan Kulkarni提供。所有播客内容(包括剧集、图形和播客描述)均由 Darshan Kulkarni 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Insider Exposes crucial missing step in Clinical Trial Agreements activation - Congruency Review Details Revealed!
In the clinical trial agreement activation pathway, the journey involves several critical steps. It begins with the signing of the Confidentiality Disclosure Agreement (CDA), followed by the study team's review of the protocol and feasibility goals. Once the study gets the green light, the congruency review phase becomes crucial. This phase kicks off with a Medicare coverage analysis to determine what falls under research billing and sponsor billing versus insurance billing.
The Medicare coverage analysis further involves creating a detailed calendar and schedule of events in the clinical trial management system. Budget negotiations come into play, and once finalized, the financial console aligns with the clinical trial management system calendar. Simultaneously, contract and informed consent negotiations occur, often involving multiple groups within the institution and various vendors.
Despite the complexity, there's a notable gap in the industry – the lack of comprehensive congruency review. This gap is observed both on the site side and the pharmaceutical side. Many times, discrepancies arise when regulatory discussions conflict with legal interpretations, and there's no final congruency review to ensure alignment between the Medicare coverage analysis, calendar, budget, contract, and informed consent form. Bridging this gap becomes pivotal to ensure a seamless and error-free process.
Support the Show.

  continue reading

85集单集

Artwork
icon分享
 
Manage episode 398035284 series 3506216
内容由Darshan Kulkarni提供。所有播客内容(包括剧集、图形和播客描述)均由 Darshan Kulkarni 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Insider Exposes crucial missing step in Clinical Trial Agreements activation - Congruency Review Details Revealed!
In the clinical trial agreement activation pathway, the journey involves several critical steps. It begins with the signing of the Confidentiality Disclosure Agreement (CDA), followed by the study team's review of the protocol and feasibility goals. Once the study gets the green light, the congruency review phase becomes crucial. This phase kicks off with a Medicare coverage analysis to determine what falls under research billing and sponsor billing versus insurance billing.
The Medicare coverage analysis further involves creating a detailed calendar and schedule of events in the clinical trial management system. Budget negotiations come into play, and once finalized, the financial console aligns with the clinical trial management system calendar. Simultaneously, contract and informed consent negotiations occur, often involving multiple groups within the institution and various vendors.
Despite the complexity, there's a notable gap in the industry – the lack of comprehensive congruency review. This gap is observed both on the site side and the pharmaceutical side. Many times, discrepancies arise when regulatory discussions conflict with legal interpretations, and there's no final congruency review to ensure alignment between the Medicare coverage analysis, calendar, budget, contract, and informed consent form. Bridging this gap becomes pivotal to ensure a seamless and error-free process.
Support the Show.

  continue reading

85集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南